Search All Jobs

Showing 1 of 1 Jobs

Instructional Design Manager

$113.2k - $169.7k/yr

Boston, MA, USA

Full-Time

Instructional Design Manager

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$113.2k - $169.7k/yr

+ Bonus + Equity Awards

Senior

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Education
Requirements
  • Expert knowledge of Articulate360, Lectora, or additional course authoring software
  • A strong desire to create, push boundaries, and take risks to engage learners
  • Superior communication skills with a keen eye for editing and style
  • Experience working with content specialists and subject matter experts across a range of disciplines
  • Strong collaborative style, with an ability to partner with multiple stakeholders
  • Understanding of how to manage multiple projects and prioritize tasks to meet deadlines
  • Demonstrated project management skills and the ability to excel in a dynamic and fast-paced environment
  • Ability to envision content that resonates with Vertex’s unique culture
  • Highest level of ethics and commitment to Vertex’s core values and beliefs
  • Bachelor’s Degree in Education, Communication or Curriculum Design
  • 5+ years of curriculum development and design experience that demonstrates deep knowledge of adult learning principles and an understanding of a professional audience
Responsibilities
  • Develop interactive and engaging learning content for scientific and technical courses
  • Partner with internal team in support of education initiatives
  • Maintain University standards of excellence when collaborating with Subject Matter Experts
  • Author course content and develop formative and summative assessments
  • Draft and/or edit scripts for voiceover artists and/or external partners
  • Create downloadable resources to support course content
  • Collaborate with the University team to ensure collateral is brand consistent
  • Ensure all courses and components are employee-centered, drive the intended learning outcomes, meet all company standards, and follow best-practices
  • Maintain curriculum assets in accordance with review cycle to ensure content remains up-to-date, innovative and cutting edge
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's partnership with Orna could lead to breakthroughs in gene therapy solutions.
  • Recent investments indicate strong investor confidence in Vertex's strategic direction.
  • Vertex's reaffirmed stock rating suggests stability and potential for steady growth.

What critics are saying

  • Increased competition in cystic fibrosis treatments could impact Vertex's market share.
  • High costs of gene-editing therapies may limit their commercial success.
  • Regulatory challenges could delay approvals for Vertex's new gene-editing therapies.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • Partnerships with Arbor and Orna enhance Vertex's gene-editing and cell therapy capabilities.
  • Vertex's innovative R&D approach sets it apart in the biotechnology industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.

GlobeNewswire
Mar 18th, 2025
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into...

MarketBeat
Feb 14th, 2025
JSF Financial LLC Invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

JSF Financial LLC invests $751,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).